RecruitingNCT07642908

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

Sponsor

University of Michigan

Enrollment

15 participants

Start Date

Sep 18, 2025

Study Type

OBSERVATIONAL

Conditions

Parkinson Disease

Summary

This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.

Eligibility

Min Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with parkinson disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 45 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.